ID   M24
AC   CVCL_D032
SY   UCLA-SO-M24; UCLA-SO-24
DR   ATCC; CRL-12270
DR   cancercelllines; CVCL_D032
DR   Cosmic; 2163789
DR   ESTDAB; ESTDAB-043
DR   ESTDAB; ESTDAB-134
DR   Wikidata; Q54903558
RX   Patent=US5840317;
RX   Patent=US5993828;
RX   PubMed=2009538;
RX   PubMed=15592718;
RX   PubMed=23851445;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12270.
CC   HLA typing: A*02:01,68:01:01; B*40:01:01,40:02; C*03:04,02:02:02; DPB1*04:01; DQB1*03:01:01,05:02; DRB1*04:01:01,16:02 (PubMed=15592718).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): ESTDAB
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 8,11
ST   D3S1358: 14,16
ST   D5S818: 13
ST   D7S820: 9
ST   FGA: 18,19
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 16
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 16
//
RX   Patent=US5840317;
RA   Morton D.L.;
RT   "Composition comprising tumor cell lines containing GD2 ganglioside
RT   GM2 ganglioside, M-TAA, and either M-urinary antigen or M-fetal
RT   antigen.";
RL   Patent number US5840317, 24-Nov-1998.
//
RX   Patent=US5993828;
RA   Morton D.L.;
RT   "Tumor associated antigen compositions and methods.";
RL   Patent number US5993828, 30-Nov-1999.
//
RX   PubMed=2009538;
RA   Mueller B.M., Romerdahl C.A., Trent J.M., Reisfeld R.A.;
RT   "Suppression of spontaneous melanoma metastasis in scid mice with an
RT   antibody to the epidermal growth factor receptor.";
RL   Cancer Res. 51:2193-2198(1991).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A.,
RA   Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//